Allergic RhinitisAP-CATNCT06828484
Allergenic Extract Standardized Cat Hair AP in an Allergic Rhinitis Model.
A study testing Allergenic Extract Standardized Cat Hair Acetone-Precipitated (AP) in people with Allergic Rhinitis, run by Queen's University at 1 site in Canada.
Trial summary
The goal of this study is to learn if a cat allergen extract known as Allergenic Extract Standardized Cat Hair Acetone Precipitated (AP Cat) can induce allergic rhinitis (AR) in a nasal allergen challenge model in cat-allergic people. The main questions this study aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Allergic Rhinitis
- What is being tested?
- Allergenic Extract Standardized Cat Hair Acetone-Precipitated (AP)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteCanada
- Study dates
- 4 Mar 2025to Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- To be considered for inclusion in this study, all participants must be:
- A healthy, ambulatory male, female, or intersex volunteer between the ages of 18 to 70 years of age.
- Able to understand and willing to provide written informed consent.
- Able and willing to comply with study requirements.
- To be enrolled as an allergic participant, participants must:
- Have a minimum 2-year history of AR symptoms upon exposure to cats.
Show all 11Show fewer
- Have a positive skin prick response to AP cat allergen, defined as a wheal diameter ≥ 5 mm compared to the negative control wheal. This result must be achieved at visit 1.
- Have a TNSS of greater than or equal to 8/12 and at least a 50% drop in PNIF in response to the allergen titration challenge at visit 1.
- To be enrolled as a non-allergic participant, participants must:
- Produce a negative skin test response to a panel of relevant aeroallergens tested at visit 1 or within 12 months before visit 1 at the research site.
- Produce a negative Nasal Allergen Challenge, defined by a TNSS response of less than 4/12 and a PNIF reduction of less than or equal to 20% after 10 minutes in response to the highest allergen concentration at visit 1.
Who cannot join
- Participant has abnormalities detected on physical examination considered by the investigator to be clinically significant.
- Participant has a history of any disease or disorder that, in the judgement of the investigator, would impact the participant's safety or the results of the study.
- Participant has a significant history of alcohol or drug abuse in the judgment of the Principal Investigator or delegate.
- Participant is pregnant, lactating, or actively trying to become pregnant.
- Participant is unable to comply with the washout periods for restricted medications.
- Participant has signs/symptoms of active seasonal AR or is allergic to a seasonal allergen that is present in the outdoor environment during visit 1 and visit 2 and which the Principal Investigator judges would impact the outcome of the study.
Show all 18Show fewer
- Participant has any structural nasal abnormalities or nasal polyps on examination or a history of frequent nose bleeding, as determined by a nasal examination at screening and prior to the NAC, in the judgement of the principal investigator.
- Participant has undergone nasal surgery within the previous 3 months before visit 1.
- Participant has experienced an upper or lower respiratory infection within 2 weeks prior to the NAC visit.
- Participant exhibits any signs or symptoms of a respiratory infection prior to any visit, as per Principal Investigator judgement.
- Participant reports a TNSS of greater than or equal to 4 prior to the titration challenge at visit 1 or immediately prior to allergen challenge at visit 2, as per Principal Investigator judgement.
- Participant reports a TNSS change of greater than 2 from baseline, after the diluent challenge at visit 1.
- Participants with asthma requiring the use of a short-acting beta agonist greater than twice a week (unless for viral asthma) or with severe asthma requiring maintenance high doses of inhaled or oral corticosteroids or biologic therapy (Omalizumab/Mepolizumab/Resilizumab).
- Participant has a history of cat allergen induced asthma, unless well controlled on low-dose inhaled corticosteroids or PRN inhaled corticosteroid/long-acting beta-agonist as per Principal Investigator discretion.
- Participant is currently receiving cat allergen specific immunotherapy or concluded a course of cat immunotherapy in the last 3 years.
- Participant has a history of positive test results for HIV, Tuberculosis (not due to vaccination), Hepatitis B (not due to vaccination) or Hepatitis C.
- Participant has received an investigational product within the previous 30 days.
- Participant is unable and/or unlikely to comprehend and/or follow the protocol over the duration of the study. Participant is unwilling to attend study visits or adhere to the study protocol, in the judgement of the Principal investigator.
Trial locations and contacts
1 site in 1 country.
Canada1 site
Kingston Health Sciences Centre - Kingston General Hospital
Kingston, Ontario, K7L2V7
About this study
Official title: Evaluating the Clinical and Biological Response of an Acetone-Precipitated Cat Hair Allergen Extract (AP Cat) in a Nasal Allergen Challenge (NAC).
The goal of this study is to learn if a cat allergen extract known as Allergenic Extract Standardized Cat Hair Acetone Precipitated (AP Cat) can induce allergic rhinitis (AR) in a nasal allergen challenge model in cat-allergic people. The main questions this study aims to answer are:
- Does AP Cat induce nasal symptoms of allergic rhinitis in cat-allergic participants when delivered intranasally?
- Does AP Cat reduce elements in the blood and nose that are known to be associated with allergies?
Read more
Both allergic and non-allergic participants will be recruited into this study.
Allergic participants will:
- Be challenged with AP Cat via the Nasal Allergen Challenge (NAC), which involves administration of this allergen extract directly into the nose.
- Have nasal fluid and blood samples collected at various timepoints up to 24 hours after exposure to the allergen in the NAC.
- Visit the study site three separate times:
- At screening (Visit 1), to determine eligibility to participate in this study
- At the baseline NAC visit (Visit 2)
- At the 24-hour post-NAC follow-up visit (Visit 3)
- Complete nasal symptom questionnaires.
- Complete a questionnaire about their regular exposure to cats.
Non-allergic participants will:
- Be challenged with AP Cat via the NAC, which involves administration of this allergen extract directly into the nose.
- Have nasal fluid and blood samples collected at various timepoints up to 24 hours after exposure to the allergen in the NAC.
- Visit the study site three separate times:
- At screening (Visit 1), to determine eligibility to participate in this study
- At the baseline NAC visit (Visit 2)
- At the 24-hour post-NAC follow-up visit (Visit 3)
- Complete nasal symptom questionnaires.
This study will compare the nasal symptoms and allergic markers collected from the nasal fluid and blood samples between allergic and non-allergic participants at baseline and various timepoints post-NAC exposure.
Read the detailed description
The purpose of this single-centre prospective cohort study is to evaluate the use of AP Cat in the NAC. Allergen extracts are used in skin prick testing, allergy research, and immunotherapy. AP Cat is a new formulation of a cat allergen extract approved for use in skin prick testing, but has not yet been studied in the NAC.
This study will enrol non-pregnant and non-lactating female and/or male participants. 15 cat-allergic participants and 5 non-allergic participants from 18-70 years old will be recruited from the Kingston, Frontenac, Lennox, and Addington region in Ontario, Canada. All 20 participants will attend three study visits: Visit 1 (Screening Visit), Visit 2 (NAC Exposure Visit), and Visit 3 (Follow-up Visit). Visit 2 will occur at least 21 days after Visit 1. Visit 3 will occur 24 hours after the onset of the NAC during visit 2. At each visit, symptom scores, nasal fluid samples, and blood samples will be collected.
The investigators hypothesize that AP Cat will induce AR-related outcomes (Total Nasal Symptom Score (TNSS), Peak Nasal Inspiratory Flow (PNIF), Total Ocular Symptom Score (TOSS), Total Rhinoconjunctivitis Symptom Score (TRSS)) in cat-allergic participants after exposure in the NAC. The investigators also hypothesize that AP Cat will increase the release of allergic mediators (Interleukin-4 (IL4),IL-5, IL-10, IL-13, Eotaxin-1, Monocyte Chemoattractant Protein-1 (MCP-1), Macrophage Inflammatory Protein-1 Beta (MIP-1β), and alarmins (IL-17E/IL-25, IL-33)) in cat-allergic participants after the NAC. Additionally, the investigators expect that nasal white blood cell counts and peripheral total immunoglobulin E (tIgE) levels will increase in cat-allergic participants after the NAC. Furthermore, the investigators hypothesize that no significant changes to nasal symptoms, allergic mediator levels, nasal eosinophil counts, or tIgE levels will occur in the non-allergic participants, which serve as controls.
- Conditions
- Allergic Rhinitis
- Being tested
- Allergenic Extract Standardized Cat Hair Acetone-Precipitated (AP)
- Keywords
- Allergy, Allergic Rhinitis, Perennial Allergies, Cat Allergies, Allergen Exposure Models, Nasal Allergen Challenge
- Medical subject headings
- Rhinitis, Allergic, Hypersensitivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Allergenic Extract Standardized Cat Hair Acetone-Precipitated (AP)Drug
Also called AP Cat
Cat-allergic and non-allergic participants will be exposed to AP Cat in the NAC.
| Study group | Role | What they receive |
|---|---|---|
| Allergic Participant AP-Cat Challenge | Experimental | Not described Receives: Drug: Allergenic Extract Standardized Cat Hair Acetone-Precipitated (AP) |
| Non-Allergic Participant AP-Cat Challenge | Experimental | Not described Receives: Drug: Allergenic Extract Standardized Cat Hair Acetone-Precipitated (AP) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total Nasal Symptom Score (TNSS)
To evaluate the effect of NAC exposure to AP Cat on TNSS (where a score of 0 indicates no nasal allergic symptoms while a score of 12 indicates the maximum nasal symptoms) compared to baseline measures in cat-allergic participants.
Measured: Pre-NAC up to 24 hours post-NAC.
Secondary outcomes (12)
Peak Nasal Inspiratory Flow (PNIF)
To evaluate the effect of NAC exposure to AP Cat on PNIF compared to baseline measures in cat-allergic participants.
Measured: Pre-NAC up to 24 hours post-NAC.
Total Ocular Symptom Score (TOSS)
To evaluate the effect of NAC exposure to AP Cat on TOSS (where a score of 0 indicates no ocular symptoms whereas a score of 9 indicates maximum ocular symptoms) compared to baseline measures in cat-allergic participants.
Measured: Pre-NAC up to 24 hours post-NAC.
Total Rhinoconjunctivitis Symptom Score (TRSS)
To evaluate the effect of NAC exposure to AP Cat on TRSS (where a score of 0 indicates no rhinoconjunctivitis symptoms whereas a score of 24 indicates maximum rhinoconjunctivitis symptoms) compared to baseline measures in cat-allergic participants.
Measured: Pre-NAC up to 24 hours post-NAC.
Safety Outcome Scoring
To evaluate the safety of NAC exposure to Allergenic Extract Standardized Cat Hair AP (coughing, wheezing, chest tightness, shortness of breath, where a score of 0 indicates no symptoms whereas a score of 12 indicates maximum symptoms).
Measured: From enrolment to the final study visit.
Concentration of alarmins (IL-17E/IL-25, IL-33) from serum.
To evaluate the effect of using AP Cat in an NAC on peripheral allergic biomarkers pre- and post-NAC.
Measured: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
Concentration of alarmins (IL-17E/IL-25, IL-33) from nasal fluid.
To evaluate the effect of using AP Cat in an NAC on nasal allergic biomarkers pre- and post-NAC.
Measured: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
Concentration of type 2 cytokines (IL-4, IL-5, IL-10, IL-13) from serum.
To evaluate the effect of using AP Cat in an NAC on peripheral allergic biomarkers pre- and post-NAC.
Measured: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
Concentration of type 2 cytokines (IL-4, IL-5, IL-10, IL-13) from nasal fluid.
To evaluate the effect of using AP Cat in an NAC on nasal allergic biomarkers pre- and post-NAC.
Measured: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
Concentration of chemokines (Eotaxin-1, MCP-1, MIP-1B) from serum.
To evaluate the effect of using AP Cat in an NAC on peripheral allergic biomarkers pre- and post-NAC.
Measured: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
Concentration of chemokines (Eotaxin-1, MCP-1, MIP-1B) from nasal fluid.
To evaluate the effect of using AP Cat in an NAC on nasal allergic biomarkers pre- and post-NAC.
Measured: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
Concentration of total immunoglobulin E from serum.
To evaluate the effect of using AP Cat in an NAC on peripheral biomarkers pre- and post-NAC.
Measured: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
White blood cell count from nasal lavage.
To evaluate the effect of using AP Cat in an NAC on nasal allergic biomarkers pre- and post-NAC.
Measured: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Feb 2025
- Study start4 Mar 2025
- Primary completion8 Jan 2026
- Study completionJun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Allergic RhinitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Model description
- Both allergic (Arm 1) and non-allergic (Arm 2) groups will receive the same intervention (AP Cat) through the NAC.
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Queen's University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Anne Ellis, Queen's University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06828484
- Sponsor's protocol ID
- AP-CAT
- Acronym
- AP-CAT
- Status last verified
- Jan 2026
- First submitted
- 11 Feb 2025
- Last updated
- 20 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating the Clinical and Biological Response of an Acetone-Precipitated Cat Hair Allergen Extract (AP Cat) in a Nasal Allergen Challenge (NAC).
- ClinicalTrials.gov ID
- NCT06828484
- Acronym / sponsor ID
- AP-CAT / AP-CAT
- Conditions
- Allergic Rhinitis
- Keywords
- Allergy, Allergic Rhinitis, Perennial Allergies, Cat Allergies, Allergen Exposure Models, Nasal Allergen Challenge
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Queen's UniversityUniversity, hospital or other
- Study start
- 4 Mar 2025 (actual)
- Primary completion
- 8 Jan 2026 (actual)
- Study completion
- Jun 2026 (estimated)
- First posted
- 14 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to learn if a cat allergen extract known as Allergenic Extract Standardized Cat Hair Acetone Precipitated (AP Cat) can induce allergic rhinitis (AR) in a nasal allergen challenge model in cat-allergic people. The main questions this study aims to answer are:
- Does AP Cat induce nasal symptoms of allergic rhinitis in cat-allergic participants when delivered intranasally?
- Does AP Cat reduce elements in the blood and nose that are known to be associated with allergies?
Both allergic and non-allergic participants will be recruited into this study.
Allergic participants will:
- Be challenged with AP Cat via the Nasal Allergen Challenge (NAC), which involves administration of this allergen extract directly into the nose.
- Have nasal fluid and blood samples collected at various timepoints up to 24 hours after exposure to the allergen in the NAC.
- Visit the study site three separate times:
- At screening (Visit 1), to determine eligibility to participate in this study
- At the baseline NAC visit (Visit 2)
- At the 24-hour post-NAC follow-up visit (Visit 3)
- Complete nasal symptom questionnaires.
- Complete a questionnaire about their regular exposure to cats.
Non-allergic participants will:
- Be challenged with AP Cat via the NAC, which involves administration of this allergen extract directly into the nose.
- Have nasal fluid and blood samples collected at various timepoints up to 24 hours after exposure to the allergen in the NAC.
- Visit the study site three separate times:
- At screening (Visit 1), to determine eligibility to participate in this study
- At the baseline NAC visit (Visit 2)
- At the 24-hour post-NAC follow-up visit (Visit 3)
- Complete nasal symptom questionnaires.
This study will compare the nasal symptoms and allergic markers collected from the nasal fluid and blood samples between allergic and non-allergic participants at baseline and various timepoints post-NAC exposure.
Detailed description
The purpose of this single-centre prospective cohort study is to evaluate the use of AP Cat in the NAC. Allergen extracts are used in skin prick testing, allergy research, and immunotherapy. AP Cat is a new formulation of a cat allergen extract approved for use in skin prick testing, but has not yet been studied in the NAC.
This study will enrol non-pregnant and non-lactating female and/or male participants. 15 cat-allergic participants and 5 non-allergic participants from 18-70 years old will be recruited from the Kingston, Frontenac, Lennox, and Addington region in Ontario, Canada. All 20 participants will attend three study visits: Visit 1 (Screening Visit), Visit 2 (NAC Exposure Visit), and Visit 3 (Follow-up Visit). Visit 2 will occur at least 21 days after Visit 1. Visit 3 will occur 24 hours after the onset of the NAC during visit 2. At each visit, symptom scores, nasal fluid samples, and blood samples will be collected.
The investigators hypothesize that AP Cat will induce AR-related outcomes (Total Nasal Symptom Score (TNSS), Peak Nasal Inspiratory Flow (PNIF), Total Ocular Symptom Score (TOSS), Total Rhinoconjunctivitis Symptom Score (TRSS)) in cat-allergic participants after exposure in the NAC. The investigators also hypothesize that AP Cat will increase the release of allergic mediators (Interleukin-4 (IL4),IL-5, IL-10, IL-13, Eotaxin-1, Monocyte Chemoattractant Protein-1 (MCP-1), Macrophage Inflammatory Protein-1 Beta (MIP-1β), and alarmins (IL-17E/IL-25, IL-33)) in cat-allergic participants after the NAC. Additionally, the investigators expect that nasal white blood cell counts and peripheral total immunoglobulin E (tIgE) levels will increase in cat-allergic participants after the NAC. Furthermore, the investigators hypothesize that no significant changes to nasal symptoms, allergic mediator levels, nasal eosinophil counts, or tIgE levels will occur in the non-allergic participants, which serve as controls.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Both allergic (Arm 1) and non-allergic (Arm 2) groups will receive the same intervention (AP Cat) through the NAC.
| Arm | Type | Receives |
|---|---|---|
| Allergic Participant AP-Cat Challenge | Experimental | Drug: Allergenic Extract Standardized Cat Hair Acetone-Precipitated (AP) |
| Non-Allergic Participant AP-Cat Challenge | Experimental | Drug: Allergenic Extract Standardized Cat Hair Acetone-Precipitated (AP) |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- A healthy, ambulatory male, female, or intersex volunteer between the ages of 18 to 70 years of age.
- Able to understand and willing to provide written informed consent.
- Able and willing to comply with study requirements.
- Have a minimum 2-year history of AR symptoms upon exposure to cats.
- Have a positive skin prick response to AP cat allergen, defined as a wheal diameter ≥ 5 mm compared to the negative control wheal. This result must be achieved at visit 1.
Key exclusion criteria (18 listed)
- Participant has abnormalities detected on physical examination considered by the investigator to be clinically significant.
- Participant has a history of any disease or disorder that, in the judgement of the investigator, would impact the participant's safety or the results of the study.
- Participant has a significant history of alcohol or drug abuse in the judgment of the Principal Investigator or delegate.
- Participant is pregnant, lactating, or actively trying to become pregnant.
- Participant is unable to comply with the washout periods for restricted medications.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Allergenic Extract Standardized Cat Hair Acetone-Precipitated (AP)Also: AP CatCat-allergic and non-allergic participants will be exposed to AP Cat in the NAC. | Drug | Allergic Participant AP-Cat Challenge, Non-Allergic Participant AP-Cat Challenge |
Primary outcome
Total Nasal Symptom Score (TNSS)
Time frame: Pre-NAC up to 24 hours post-NAC.
To evaluate the effect of NAC exposure to AP Cat on TNSS (where a score of 0 indicates no nasal allergic symptoms while a score of 12 indicates the maximum nasal symptoms) compared to baseline measures in cat-allergic participants.
12 secondary outcomes
Peak Nasal Inspiratory Flow (PNIF)
Time frame: Pre-NAC up to 24 hours post-NAC.
Total Ocular Symptom Score (TOSS)
Time frame: Pre-NAC up to 24 hours post-NAC.
Total Rhinoconjunctivitis Symptom Score (TRSS)
Time frame: Pre-NAC up to 24 hours post-NAC.
Safety Outcome Scoring
Time frame: From enrolment to the final study visit.
Concentration of alarmins (IL-17E/IL-25, IL-33) from serum.
Time frame: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
Concentration of alarmins (IL-17E/IL-25, IL-33) from nasal fluid.
Time frame: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
Concentration of type 2 cytokines (IL-4, IL-5, IL-10, IL-13) from serum.
Time frame: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
Concentration of type 2 cytokines (IL-4, IL-5, IL-10, IL-13) from nasal fluid.
Time frame: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
Concentration of chemokines (Eotaxin-1, MCP-1, MIP-1B) from serum.
Time frame: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
Concentration of chemokines (Eotaxin-1, MCP-1, MIP-1B) from nasal fluid.
Time frame: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
Concentration of total immunoglobulin E from serum.
Time frame: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
White blood cell count from nasal lavage.
Time frame: Screening, baseline, 3 hours post-NAC, 6 hours post-NAC, 24 hours post-NAC.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Allergic Rhinitis
Not yet recruitingPhase 1
Safety and Tolerability of Fluticasone Propionate 10% Nasal Insert in Participants With Chronic Allergic Rhinitis
Chronic Allergic Rhinitis
RecruitingPhase 3
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-063.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
RecruitingPhase 3
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Enrolling by invitationObservational study
Allergy, Asthma, and Atopic Eczema in Finland
Asthma, Asthma in Children
Not yet recruitingObservational study
Prevelance of Bronchial Asthma and Allergic Rhinitis Among Children With Nephrotic Syndrom at Sohag University Hospital
Allergic Diseases in Nephrotic Children, Nephrotic Syndrom
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Allergenic Extract Standardized Cat Hair Acetone-Precipitated (AP) in people with Allergic Rhinitis, run by Queen's University at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total Nasal Symptom Score (TNSS) (time frame: Pre-NAC up to 24 hours post-NAC.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026.